Related Experiment Video
Updated: Jul 6, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Evidence of acute pancreatitis in a patient with radioresistant-differentiated thyroid cancer
Alan N Elias1, Paul Lizotte, Heather Hofflich
1Department of Medicine and Endocrinology, University of California, Irvine, Medical Center, Orange, CA 92868, USA. anelias@uci.edu
Abstract:
Peroxisome proliferator-activated receptor (PPAR) agonists are sometimes used in patients with radioiodine-resistant differentiated thyroid cancers in order to effect further differentiation of the tumor and increase the chance of therapeutic success with subsequent doses of radioiodine. PPAR agonists are reportedly protective of the pancreas and have been proposed as agents that might be useful in the prevention of pancreatitis. In this report, we describe a patient treated with the PPAR agonist rosiglitazone for thyroid cancer who showed imaging abnormalities on PET scan and biochemical evidence of acute pancreatitis. Despite evidence of acute pancreatitis, the etiology of which is unclear, the patient remained asymptomatic. It is speculated that the lack of symptoms in this patient was due to the suppression by rosiglitazone of proinflammatory cytokines.
Related Concept Videos
Chronic Pancreatitis I: Introduction
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Acute Pancreatitis II: Clinical Manifestations and Management
Graves Disease II: Pathophysiology
Acute Pancreatitis I: Introduction
Hyperthyroidism I: Introduction

